harmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) — PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration (USFDA) in advance of its pre-IND meeting scheduled for later this month. PharmAla will be requesting FDA... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )